According to the 2023 NCCN guidelines, cardiac involvement can be determined by excluding other cardiac diseases if the ventricular wall thickness exceeds 12 mm and NT-proBNP elevation is not due to renal impairment or atrial fibrillation [11]. This evidence concerns the gene NPPB and atrial fibrillation.